16 results
424B5
IFRX
InflaRx N.V.
13 Apr 23
Prospectus supplement for primary offering
8:48am
of the applicable patent, specifically cover the use of such antibodies in treating diseases such as ischemia and reperfusion related injuries, acute lung
424B5
IFRX
InflaRx N.V.
11 Apr 23
Prospectus supplement for primary offering
4:11pm
on the jurisdiction of the applicable patent, specifically cover the use of such antibodies in treating diseases such as ischemia and reperfusion related injuries
6-K
EX-10.1
IFRX
InflaRx N.V.
21 Dec 22
Current report (foreign)
7:45am
the Regulatory Documents at its own expense and risk and shall hold INFLARX harmless at all times of any liabilities, claims for damages or personal injuries … that and if so to which extent such damages or injuries were due to gross negligence or willful misconduct on the part of INFLARX. Staidson shall use
424B5
32vzcll fb
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
ei4t87k 2nccgsl3r4z4
24 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
5d0hsl
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
ayozs vkvmtysltr9y
8 Jul 20
Shelf registration (foreign)
12:00am
20-F/A
xffcm82exhye5c zaj
29 Mar 19
Annual report (foreign) (amended)
4:23pm
424B4
9uzp ntckbk4s91l
7 May 18
Prospectus supplement with pricing info
4:47pm
F-1
bl85t2t
2 May 18
Registration statement (foreign)
7:10am
20-F
08xa9upe0pptpr9t3wh
29 Mar 18
Annual report (foreign)
12:00am
- Prev
- 1
- Next